[ Back to EurekAlert! ]

PUBLIC RELEASE DATE:
23-Aug-2011

[ | E-mail ] Share Share

Contact: Dr. Korbinian Grote
grote@genomatix.de
Genomatix Software GmbH

Genomatix wins "Most Creative Visualization" award at iDEA Challenge 2011

Genomatix' solutions for NGS data analysis awarded in the commercial category at Illumina's San Diego iDEA conference

IMAGE: The trophy for Illumina's iDEA Challenge 2011 "Most Creative Visualization " award in the commercial category has been won by Genomatix Software, Munich.

Click here for more information.

Genomatix has recently won the "Most Creative Visualization" award in the "commercial" category of Illumina's Data Excellence (iDEA) Challenge 2011, an achievement we are extremely proud of. iDEA is Illumina's program designed to challenge the scientific community to develop new and creative visualization and data analysis techniques.

"The iDEA challenge really sparked our interest from the very first moment we heard about it. Genomatix is a scientific company at heart, and we felt that getting our hands on a high quality, widely diverse dataset like the one Illumina provided for the Challenge would be an ideal test for our scientific approach to data analysis... which is to combine multiple lines of evidence to get from sequencing data to biological knowledge" says Dr. Jochen Supper, who presented Genomatix' submission at the San Diego iDEA meeting.

Dr. Martin Seifert, CEO of Genomatix, adds: "The Challenge was judged by a panel of renowned experts from the scientific community, and this is a great endorsement of the work we've done to date, as well as a significant motivation to push even harder in the future. Genomatix has always focused on providing intuitive interfaces and easy-to-understand visualizations. The combination of our scientifically validated algorithms and wealth of annotation data allows us to offer a comprehensive platform solution for Next Generation Sequencing data analysis. With the iDEA data being generated from cancer cell lines it also underlines the increasing relevance of our technologies for medical applications."

###



[ Back to EurekAlert! ] [ | E-mail Share Share ]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.